Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.
Business Model:
Revenue: $13.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Perceptive Advisors Information
Geographic Data
Address: 499 Park Ave
City: New York
State: NY
Zip: 10022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Linkedin
Crunchbase
Metrics
2,160,524Website Global Rank
9,065Website Monthly Traffic
Twitter Followers
Description
Perceptive Advisors, LLC is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while making its investments. The firm typically invests in biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.
Contact Phone:
+16462055340
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2022 | Surf Bio | Seed | 16M |
| 12/2020 | Solid Biosciences | Post-IPO Equity | 0 |
| 7/2015 | Outlook Therapeutics | Venture Round | 31M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 12/2005 | EUSA Pharma | Venture Round | 0 |
| 11/2020 | Adagio Medical | Series E | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 4/2020 | COMPASS Pathways | Series B | 0 |
| 6/2015 | Alliqua BioMedical | Post-IPO Debt | 15.5M |
| 9/2021 | Emulate | Series E | 82M |
| 9/2021 | SomaLogic | Post-IPO Equity | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 9/2014 | Affimed | Debt Financing | 14M |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 9/2020 | Willow | Series C | 0 |
| 5/2017 | Home Dialysis Plus | Series C | 76.5M |
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 5/2016 | AVEO Oncology | Post-IPO Equity | 17M |
| 7/2019 | Frequency Therapeutics | Series C | 0 |
| 4/2021 | Forge Biologics | Series B | 120M |
| 9/2018 | Lyra Therapeutics | Series B | 0 |
| 1/2016 | Arno Therapeutics | Post-IPO Equity | 0 |
| 10/2021 | Honor | Debt Financing | 300M |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 7/2018 | Alector | Series E | 133M |
| 9/2021 | Hancock Jaffe Laboratories | Post-IPO Equity | 20M |
| 8/2016 | Arno Therapeutics | Post-IPO Equity | 8M |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 10/2021 | Science 37 | Post-IPO Equity | 0 |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 12/2019 | Quellis Biosciences | Series A | 0 |
| 7/2014 | Virobay | Series B | 8M |
| 3/2020 | immatics biotechnologies | Post-IPO Equity | 0 |
| 2/2020 | Agile Therapeutics | Post-IPO Debt | 20M |
| 9/2021 | A-Alpha Bio | Series A | 20M |
| 1/2022 | AvengeBio | Series A | 0 |
| 6/2019 | PanTheryx | Venture Round | 50M |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 1/2022 | Orchestra BioMed | Series D | 0 |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 5/2017 | Xontogeny | Series A | 15M |
| 6/2021 | PROCEPT BioRobotics | Series G | 0 |
| 5/2019 | ArcherDX | Series B | 60M |
| 11/2015 | Solid Biosciences | Series B | 42.5M |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 4/2020 | Dynacure | Series C | 54.2M |
| 9/2018 | Vapotherm | Series D | 0 |
| 12/2019 | ArcherDX | Series C | 0 |
| 9/2020 | Zymergen | Series D | 300M |
| 3/2015 | Champions Oncology | Post-IPO Equity | 14M |
| 7/2019 | Neptune Wellness Solutions | Post-IPO Equity | 41.4M |
| 11/2020 | Prometheus Biosciences | Equity | 130M |
| 2/2018 | PROCEPT BioRobotics | Series E | 0 |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 1/2021 | Earli | Series A | 40M |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 10/2021 | Twin Health | Series C | 155M |
| 1/2021 | Impulse Dynamics | Series D | 60M |
| 6/2020 | DNAnexus | Series G | 0 |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 11/2017 | Counsyl | Equity | 80M |
| 5/2017 | Outset Medical | Series C | 0 |
| 6/2020 | Fulcrum Therapeutics | Post-IPO Equity | 0 |
| 5/2021 | Cue | Venture Round | 235M |
| 5/2020 | Nautilus Biotechnology | Series B | 76M |
| 3/2019 | Saama | Venture Round | 40M |
| 6/2016 | VitalConnect | Series B | 18M |
| 10/2020 | LianBio | Series A | 0 |
| 7/2018 | Athenex | Post-IPO Equity | 50M |
| 4/2019 | Kindbody | Series A | 15M |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 1/2020 | Sonendo | Venture Round | 85M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 12/2016 | VBI Vaccines | Post-IPO Equity | 10.6M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 12/2016 | VBI Vaccines | Post-IPO Debt | 13M |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 1/2021 | Clover Health | Post-IPO Equity | 400M |
| 4/2017 | Singulex | Debt Financing | 50M |
| 8/2020 | Freenome | Series C | 270M |
| 1/2018 | AEGEA Medical | Series D | 0 |
| 6/2020 | C4 Therapeutics | Debt Financing | 20M |
| 5/2018 | Rain Therapeutics | Series A | 18.4M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 8/2019 | Landos Biopharma | Series B | 60M |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 9/2022 | InSightec | Debt Financing | 100M |
| 8/2018 | Outset Medical | Series D | 0 |
| 8/2016 | Vyome Therapeutics | Series C | 14M |
| 8/2021 | Bridge to Life | Venture Round | 56M |
| 5/2020 | Omada Health | Venture Round | 57M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 2/2019 | ADMA Biologics | Post-IPO Debt | 72.5M |
| 9/2022 | SpringWorks Therapeutics | Post-IPO Equity | 225M |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 9/2017 | Landos Biopharma | Series A | 10M |
| 10/2014 | Zynerba Pharmaceuticals | Venture Round | 13M |
| 10/2013 | Arno Therapeutics | Post-IPO Equity | 0 |
| 1/2018 | Vitruvias Therapeutics | Series A | 11.5M |
| 3/2021 | Scribe Therapeutics | Series B | 100M |
| 7/2020 | Pear Therapeutics | Debt Financing | 50M |
| 6/2015 | Outset Medical | Debt Financing | 45M |
| 9/2016 | Establishment Labs | Debt Financing | 15M |
| 8/2018 | ReViral | Series B | 0 |
| 7/2016 | VBI Vaccines | Post-IPO Equity | 0 |
| 12/2021 | Freenome | Series D | 300M |
| 11/2021 | Sermonix | Series A | 40M |
| 5/2019 | Athenex | Post-IPO Equity | 100M |
| 6/2020 | AsclepiX Therapeutics | Series A | 35M |
| 4/2018 | Kodiak Sciences | Convertible Note | 33M |
| 7/2019 | Foamix | Post-IPO Debt | 64M |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 3/2022 | VivoSense | Series A | 0 |
| 9/2015 | Outlook Therapeutics | Venture Round | - |
| 11/2022 | Biodesix | Post-IPO Debt | 50M |
| 1/2021 | Affinivax | Series C | 226M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 1/2021 | DarioHealth | Post-IPO Equity | 70M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 8/2017 | Molecular Templates | Post-IPO Equity | 60M |
| 12/2016 | Motus GI | Venture Round | 0 |
| 7/2019 | Kronos Bio | Series A | 105M |
| 8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
| 12/2016 | Vensun Pharmaceuticals | Series C | 22.5M |
| 12/2020 | Neuron23 | Series B | 80M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 7/2020 | Kindbody | Series B | 0 |
| 10/2020 | AavantiBio | Series A | 0 |
| 1/2020 | Lyra Therapeutics | Series C | 0 |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 5/2020 | Atea | Series D | 215M |
| 5/2007 | Spectrum Pharmaceuticals | Post-IPO Equity | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 7/2020 | Forge Biologics | Series A | 40M |
| 5/2021 | Juno Diagnostics | Series A | 25M |
| 3/2019 | Orchestra BioMed | Series B | 34M |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 3/2022 | DNAnexus | Series H | 200M |
| 7/2019 | Beta Bionics | Series B | 63M |
| 10/2016 | True North Therapeutics | Series D | 45M |
| 10/2014 | Invitae | Series F | 0 |
| 11/2015 | Vapotherm | Series C | 0 |
| 4/2019 | SpringWorks Therapeutics | Series B | 125M |
| 7/2019 | Freenome | Series B | 160M |
| 2/2022 | Endeavor BioMedicines | Series B | 101M |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 8/2020 | Kronos Bio | Private Equity Round | 155M |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 4/2014 | Otonomy | Series D | 49M |
| 8/2020 | Taysha Gene Therapies | Series B | 0 |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 7/2021 | Point Biopharma | Post-IPO Equity | 0 |
| 9/2022 | Solid Biosciences | Post-IPO Equity | 75M |
| 4/2021 | Icosavax | Series B | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 6/2021 | Kindbody | Series C | 0 |
| 5/2021 | Affinia Therapeutics | Series B | 0 |
| 3/2022 | Neuron23 | Series C | 0 |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2020 | Athira Pharma | Series B | 85M |
| 5/2023 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 8/2021 | Genome Medical | Series C | 0 |
| 6/2019 | Genome Medical | Series B | 23M |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 5/2019 | Confo Therapeutics | Series A | 33.6M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 6/2021 | Nautilus Biotechnology | Post-IPO Equity | 0 |
| 5/2017 | Vapotherm | Series D | 0 |
| 3/2021 | OnKure | Series B | 56.6M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 1/2021 | MIVI Neuroscience | Series B | 35M |
| 3/2021 | Crossover Health | Series D | 0 |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 11/2014 | Blueprint Medicines | Series C | 50M |
| 9/2021 | HilleVax | Equity | 135M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 8/2019 | Oncorus | Series B | 0 |
| 12/2018 | Relay Therapeutics | Series C | 0 |
| 1/2016 | Zymeworks | Series A | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 12/2021 | Hyperfine | Post-IPO Equity | 0 |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 9/2018 | Allogene | Convertible Note | 0 |
| 1/2021 | IsoPlexis | Series D | 85M |
| 3/2010 | Sevion Therapeutics | Post-IPO Equity | 0 |
| 6/2020 | CereVasc | Series A | 44M |
| 8/2020 | Metabolon | Venture Round | 72M |
| 8/2022 | MeiraGTx | Post-IPO Debt | 75M |
| 4/2021 | Renovia | Series C | 0 |
| 3/2020 | Zucara Therapeutics | Series A | 21M |
| 1/2021 | IsoPlexis | Debt Financing | 50M |
| 6/2016 | Corbus Pharmaceuticals | Post-IPO Equity | 14.8M |
| 11/2018 | Medicrea | Post-IPO Debt | 30M |
| 3/2021 | Absci | Venture Round | 0 |
| 3/2018 | Molecular Templates | Post-IPO Debt | 10M |
| 8/2016 | Aquestive Therapeutics | Debt Financing | 50M |
| 5/2015 | REGENXBIO | Series D | 0 |
| 8/2018 | Renovia | Series B | 32.3M |
| 8/2020 | ReViral | Series C | 0 |
| 7/2019 | AgaMatrix | Debt Financing | 56M |
| 8/2017 | Dova Pharmaceuticals | Post-IPO Equity | - |
| 5/2017 | Synlogic | Series C | 42M |
| 1/2019 | Vyome Therapeutics | Series D | 22M |
| 7/2020 | Genome Medical | Series B | 0 |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
| 2/2018 | Partner Therapeutics | Series A | 60M |
| 8/2022 | MeiraGTx | Post-IPO Debt | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 4/2022 | Surf Bio | Seed Round | 0 |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | VivoSense | Series A | 0 |
| 3/2022 | Neuron23 | Series C | 0 |
| 3/2022 | DNAnexus | Series H | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
